David Siegel, MD, PhD, on Relapsed / Refractory Multiple Myeloma: Final Results From the ASPIRE Trial

Posted: Monday, December 11, 2017

David Siegel, MD, PhD, of the John Theurer Cancer Center at Hackensack University Medical Center, discusses study findings on overall survival of patients treated with carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone.